JP2024516376A5 - - Google Patents
Info
- Publication number
- JP2024516376A5 JP2024516376A5 JP2023563189A JP2023563189A JP2024516376A5 JP 2024516376 A5 JP2024516376 A5 JP 2024516376A5 JP 2023563189 A JP2023563189 A JP 2023563189A JP 2023563189 A JP2023563189 A JP 2023563189A JP 2024516376 A5 JP2024516376 A5 JP 2024516376A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- dna
- section
- composition according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176225P | 2021-04-17 | 2021-04-17 | |
| US63/176,225 | 2021-04-17 | ||
| PCT/US2022/025075 WO2022221696A1 (en) | 2021-04-17 | 2022-04-15 | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516376A JP2024516376A (ja) | 2024-04-15 |
| JP2024516376A5 true JP2024516376A5 (enExample) | 2025-04-22 |
Family
ID=81581217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563189A Pending JP2024516376A (ja) | 2021-04-17 | 2022-04-15 | Ｄｎａ依存性プロテインキナーゼの阻害剤ならびにその組成物及び使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240300977A1 (enExample) |
| EP (1) | EP4323360A1 (enExample) |
| JP (1) | JP2024516376A (enExample) |
| KR (1) | KR20240017791A (enExample) |
| CN (1) | CN117940426A (enExample) |
| AU (1) | AU2022258733A1 (enExample) |
| BR (1) | BR112023021429A2 (enExample) |
| CA (1) | CA3216875A1 (enExample) |
| CL (1) | CL2023003079A1 (enExample) |
| CO (1) | CO2023015478A2 (enExample) |
| CR (1) | CR20230535A (enExample) |
| IL (1) | IL307740A (enExample) |
| MX (1) | MX2023012236A (enExample) |
| TW (1) | TW202309034A (enExample) |
| WO (1) | WO2022221696A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2023220418A2 (en) * | 2022-05-13 | 2023-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| WO2024191996A1 (en) * | 2023-03-13 | 2024-09-19 | Incyte Corporation | Bicyclic ureas as kinase inhibitors |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1021549A2 (en) | 1997-09-19 | 2000-07-26 | Sequitur, Inc. | SENSE mRNA THERAPY |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| DK3558997T3 (da) * | 2016-12-20 | 2021-04-19 | Astrazeneca Ab | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer |
| EP3688162B1 (en) | 2017-09-29 | 2024-03-06 | Intellia Therapeutics, Inc. | Formulations |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| MX2021003455A (es) | 2018-10-02 | 2021-09-21 | Intellia Therapeutics Inc | Lípidos con amina ionizables. |
| CN119285480A (zh) | 2018-12-05 | 2025-01-10 | 英特利亚治疗股份有限公司 | 改性的胺脂质 |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| US20210008161A1 (en) * | 2019-06-17 | 2021-01-14 | Crispr Therapeutics Ag | Methods and compositions for improved homology directed repair |
| EP4022057A1 (en) * | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
| WO2021104277A1 (zh) * | 2019-11-25 | 2021-06-03 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的嘧啶并咪唑类化合物 |
| KR102786205B1 (ko) * | 2019-12-31 | 2025-03-31 | 청두 바이위 파머수티컬 씨오., 엘티디 | 퓨린 유도체 및 의학에서의 그의 용도 |
| CA3192868A1 (en) * | 2020-09-24 | 2022-03-31 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
-
2022
- 2022-04-15 US US18/287,227 patent/US20240300977A1/en active Pending
- 2022-04-15 KR KR1020237039428A patent/KR20240017791A/ko active Pending
- 2022-04-15 TW TW111114469A patent/TW202309034A/zh unknown
- 2022-04-15 CA CA3216875A patent/CA3216875A1/en active Pending
- 2022-04-15 WO PCT/US2022/025075 patent/WO2022221696A1/en not_active Ceased
- 2022-04-15 CN CN202280042815.9A patent/CN117940426A/zh active Pending
- 2022-04-15 JP JP2023563189A patent/JP2024516376A/ja active Pending
- 2022-04-15 AU AU2022258733A patent/AU2022258733A1/en active Pending
- 2022-04-15 IL IL307740A patent/IL307740A/en unknown
- 2022-04-15 CR CR20230535A patent/CR20230535A/es unknown
- 2022-04-15 BR BR112023021429A patent/BR112023021429A2/pt not_active Application Discontinuation
- 2022-04-15 MX MX2023012236A patent/MX2023012236A/es unknown
- 2022-04-15 EP EP22721588.6A patent/EP4323360A1/en active Pending
-
2023
- 2023-10-16 CL CL2023003079A patent/CL2023003079A1/es unknown
- 2023-11-16 CO CONC2023/0015478A patent/CO2023015478A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12559536B2 (en) | CD33 specific chimeric antigen receptors | |
| US12344651B2 (en) | CD19 and CD22 chimeric antigen receptors and uses thereof | |
| US20240316107A1 (en) | Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 | |
| KR102883631B1 (ko) | 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법 | |
| CN115151275A (zh) | 用于向细胞递送核酸的组合物和方法 | |
| KR20180133480A (ko) | 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법 | |
| US20220211757A1 (en) | Engineered gamma delta t cells and methods of making and using thereof | |
| US12569516B2 (en) | Subject-specific tumor inhibiting cells and the use thereof | |
| CN107002036A (zh) | 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法 | |
| CN113660942A (zh) | 嵌合细胞因子受体 | |
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| CN114921417B (zh) | 双基因定点整合通用型car-t细胞的制备方法及其应用 | |
| CN118853582A (zh) | 基因编辑的肿瘤浸润淋巴细胞及其在免疫细胞治疗中的应用 | |
| US11859207B2 (en) | Artificial antigen-presenting cell prepared from HLA-null cell line by using multiplex CRISPR-CAS9 system and use thereof | |
| US20220202900A1 (en) | Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia | |
| US20240316106A1 (en) | Methods for generating primary immune cells | |
| US20230190780A1 (en) | Methods for immunotherapy | |
| HK40062145B (en) | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | |
| CN117778328A (zh) | 一种通用型bcma car-t细胞的增殖方法 | |
| CN116904514A (zh) | 用双aav载体同步定点基因编辑制备car-t细胞的方法 | |
| HK40082080A (en) | Compositions and methods for delivery of nucleic acids to cells |